Biogen (Germany) Today
| IDP Stock | 152.40 2.65 1.77% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Biogen is selling for under 152.40 as of the 24th of November 2024; that is 1.77 percent increase since the beginning of the trading day. The stock's last reported lowest price was 150.4. Biogen has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Biogen Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of December 2022 and ending today, the 24th of November 2024. Click here to learn more.
Moving together with Biogen Stock
| 0.87 | LLY | Eli Lilly | PairCorr |
| 0.65 | PFE | Pfizer Inc | PairCorr |
| 0.91 | ZEG | AstraZeneca PLC | PairCorr |
| 0.63 | AMG | Amgen Inc | PairCorr |
Moving against Biogen Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Biogen Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Biogen's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Biogen or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Pres | Christopher Viehbacher |
| Business Concentration | Drug Manufacturers-General, Healthcare (View all Sectors) |
Biogen Inc (IDP) is traded on XETRA Stock Exchange in Germany and employs 8,725 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 36.46 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biogen's market, we take the total number of its shares issued and multiply it by Biogen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Biogen Inc operates under Healthcare sector and is part of Drug Manufacturers-General industry. The entity has 144.49 M outstanding shares.
Biogen generates positive cash flow from operations, but has no cash available
Check Biogen Probability Of Bankruptcy
Ownership AllocationBiogen holds a total of 144.49 Million outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Biogen Ownership Details
Biogen Inc Risk Profiles
Although Biogen's alpha and beta are two of the key measurements used to evaluate Biogen's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.14 | |||
| Standard Deviation | 1.65 | |||
| Variance | 2.71 | |||
| Risk Adjusted Performance | (0.12) |
Biogen Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Biogen without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
Biogen Corporate Management
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robin Kramer | VP Officer | Profile | |
| Sanjay Jariwala | VP Medical | Profile | |
| Susan Esq | Chief VP | Profile | |
| Ginger Gregory | Ex Officer | Profile | |
| Anabella Villalobos | Head Sciences | Profile |
Additional Tools for Biogen Stock Analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.